- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 192548, 5 pages
Expression of Bmi-1 in Pediatric Brain Tumors as a New Independent Prognostic Marker of Patient Survival
1Department of Genetics, Faculty of Biological Science, Shahid Beheshti University (GC), Tehran 1983963113, Iran
2Laser and Plasma Research Institute, Shahid Beheshti University (GC), Tehran 1983963113, Iran
3Department of Pediatrics, Shahid Beheshti University of Medical Sciences, Mofid Children’s Hospital, Tehran, Iran
4Pediatrics Infectious Research Center (PIRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Received 2 April 2013; Accepted 18 June 2013
Academic Editor: Natasa Tosic
Copyright © 2013 Shirin Farivar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. Li, T. D. Thompson, J. W. Miller, L. A. Pollack, and S. L. Stewart, “Cancer incidence among children and adolescents in the United States, 2001–2003,” Pediatrics, vol. 121, no. 6, pp. e1470–e1477, 2008.
- D. Faury, A. Nantel, S. E. Dunn et al., “Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors,” Journal of Clinical Oncology, vol. 25, no. 10, pp. 1196–1208, 2007.
- T. Sung, D. C. Miller, R. L. Hayes, M. Alonso, H. Yee, and E. W. Newcomb, “Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas,” Brain Pathology, vol. 10, no. 2, pp. 249–259, 2000.
- G. Perilongo, “Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma,” Journal of Neuro-Oncology, vol. 75, no. 3, pp. 301–307, 2005.
- P. Kaatsch, C. H. Rickert, J. Kühl, J. Schüz, and J. Michaelis, “Populationbased epidemiologic data on brain tumors in German children,” Cancer, vol. 92, no. 12, pp. 3155–3164, 2001.
- J. A. Simon and R. E. Kingston, “Mechanisms of Polycomb gene silencing: knowns and unknowns,” Nature Reviews Molecular Cell Biology, vol. 10, no. 10, pp. 697–708, 2009.
- A. Sparmann and M. Van Lohuizen, “Polycomb silencers control cell fate, development and cancer,” Nature Reviews Cancer, vol. 6, no. 11, pp. 846–856, 2006.
- V. Orlando, “Polycomb, epigenomes, and control of cell identity,” Cell, vol. 112, no. 5, pp. 599–606, 2003.
- A. V. Molofsky, R. Pardal, T. Iwashita, I.-K. Park, M. F. Clarke, and S. J. Morrison, “Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation,” Nature, vol. 425, no. 6961, pp. 962–967, 2003.
- I.-K. Park, D. Qian, M. Kiel et al., “Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells,” Nature, vol. 423, no. 6937, pp. 302–305, 2003.
- S. Vonlanthen, J. Heighway, H. J. Altermatt et al., “The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression,” British Journal of Cancer, vol. 84, no. 10, pp. 1372–1376, 2001.
- F. J. Van Kemenade, F. M. Raaphorst, T. Blokzijl et al., “Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma,” Blood, vol. 97, no. 12, pp. 3896–3901, 2001.
- J. H. Kim, S. Y. Yoon, C.-N. Kim et al., “The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins,” Cancer Letters, vol. 203, no. 2, pp. 217–224, 2004.
- A. Honig, C. Weidler, S. Häusler et al., “Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer,” Anticancer Research, vol. 30, no. 5, pp. 1559–1564, 2010.
- S. Balasubramanian, K. Lee, G. Adhikary, R. Gopalakrishnan, E. A. Rorke, and R. L. Eckert, “The Bmi-1 polycomb group gene in skin cancer: regulation of function by (-)-epigallocatechin-3-gallate,” Nutrition Reviews, vol. 66, no. 1, pp. S65–S68, 2008.
- H. Cui, B. Hu, T. Li et al., “Bmi-1 is essential for the tumorigenicity of neuroblastoma cells,” The American Journal of Pathology, vol. 170, no. 4, pp. 1370–1378, 2007.
- L.-B. Song, M.-S. Zeng, W.-T. Liao et al., “Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells,” Cancer Research, vol. 66, no. 12, pp. 6225–6232, 2006.
- Z. K. Qin, J. A. Yang, Y. L. Ye et al., “Expression of Bmi-1 is a prognostic marker in bladder cancer,” BMC Cancer, vol. 9, no. 61, 2009.
- J.-H. Liu, L.-B. Song, X. Zhang et al., “Bmi-1 expression predicts prognosis for patients with gastric carcinoma,” Journal of Surgical Oncology, vol. 97, no. 3, pp. 267–272, 2008.
- F. Zhang, Z.-M. Wang, H.-Y. Liu et al., “Application of RT-PCR in formalin-fixed and paraffin-embedded lung cancer tissues,” Acta Pharmacologica Sinica, vol. 31, no. 1, pp. 111–117, 2010.
- D. Miltenburg, D. F. Louw, and G. R. Sutherland, “Epidemiology of childhood brain tumors,” Canadian Journal of Neurological Sciences, vol. 23, no. 2, pp. 118–122, 1996.
- I. F. Pollack, “Brain tumors in children,” The New England Journal of Medicine, vol. 331, no. 22, pp. 1500–1507, 1994.
- F. Sala, E. Colarusso, C. Mazza, A. Talacchi, and A. Bricolo, “Brain tumors in children under 3 years of age: recent experience (1987–1997) in 39 patients,” Pediatric Neurosurgery, vol. 31, no. 1, pp. 16–26, 1999.
- M. Al-Hajj and M. F. Clarke, “Self-renewal and solid tumor stem cells,” Oncogene, vol. 23, no. 43, pp. 7274–7282, 2004.
- S. K. Singh, I. D. Clarke, T. Hide, and P. B. Dirks, “Cancer stem cells in nervous system tumors,” Oncogene, vol. 23, no. 43, pp. 7267–7273, 2004.
- M. Sawa, K. Yamamoto, T. Yokozawa et al., “BMI-1 is highly expressed in M0-subtype acute myeloid leukemia,” International Journal of Hematology, vol. 82, no. 1, pp. 42–47, 2005.
- C. Leung, M. Lingbeek, O. Shakhova et al., “Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas,” Nature, vol. 428, no. 6980, pp. 337–341, 2004.
- J. T. Romer, H. Kimura, S. Magdaleno et al., “Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/-p53-/- mice,” Cancer Cell, vol. 6, no. 3, pp. 229–240, 2004.